Geron Corporation

5 months ago · seekingalpha.com

Geron Corporation (GERN) Q1 2026 Earnings Call Transcript

5 months ago · zacks.com

Geron (GERN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.

5 months ago · globenewswire.com

Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million Company to host conference call and webcast today, May 6, 2026, at 8:00 a.m.

5 months ago · globenewswire.com

FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences: Bank of America Securities 2026 Healthcare Conference Presentation on Tuesday, May 12 at 4:35 p.m.

5 months ago · globenewswire.com

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

5 months ago · globenewswire.com

FOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 2,500,000 shares of Geron common stock to Timothy Williams, Geron's new Executive Vice President, Chief Legal Officer and Corporate Secretary, as an inducement material to his acceptance of employment with Geron.

5 months ago · globenewswire.com

Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies

6 months ago · globenewswire.com

FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET.

6 months ago · globenewswire.com

Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies

7 months ago · seekingalpha.com

Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript